The U.S. Department of Justice has issued a directive signaling enhanced enforcement scrutiny for FDA-regulated industries, according to Holland & Knight. The signal extends to cosmetics manufacturers and brand owners under the Federal Food, Drug, and Cosmetic Act. The 2023 Modernization of Cosmetics Regulation Act widened the perimeter through registration, listing, and substantiation rules.

What does the directive change?

The directive reframes how DOJ and FDA-regulated sectors interact. Rather than waiting for referrals, DOJ now flags a proactive posture. Holland & Knight's alert frames the development as a signal that companies inside the FDA perimeter should expect closer review of compliance, labeling, and reporting. Officers should test whether audit cycles, supplier files, and adverse event logs can withstand federal examination. The change matters most to companies that have treated FDA overlap as theoretical.

The plain takeaway: the bar for routine documentation has moved up.

Why cosmetics companies sit inside the perimeter

Cosmetics regulation expanded substantially under MoCRA. The 2023 law mandated:

• Facility registration with FDA
• Product listing for each cosmetic placed on the U.S. market
• Serious adverse event reporting within 15 business days
• Safety substantiation before distribution
• Fragrance allergen disclosure preparation

A DOJ directive that elevates FDA-regulated industries raises the stakes for any company whose records, claims, or supply chain documentation could draw federal attention. Brand owners who rely on contract manufacturers inherit this exposure through their specifications, master formulas, and quality agreements. Even companies that previously operated below FDA's enforcement threshold now sit within a larger net.

The plain takeaway: every cosmetic on the U.S. market sits inside an enforcement perimeter DOJ has decided to widen.

What the alert does not yet specify

The headline-level summary published by Holland & Knight does not name a specific industry, deadline, monetary threshold, or enforcement action. Compliance teams will need the full alert text to determine whether the directive targets particular product categories, sets a review window, or modifies DOJ-FDA coordination protocols on parallel proceedings. The likely next data point is the publication of the full Holland & Knight analysis and any companion DOJ memorandum or press release. Until those documents surface, scope remains undefined.

The plain takeaway: until the underlying documents land, the directive remains directional rather than operational.

What the development means for procurement and formulation

Procurement teams that source ingredients, packaging, or contract manufacturing from suppliers with weak documentation will absorb most of the downstream risk. Formulators whose safety substantiation rests on outdated or incomplete toxicology files face parallel exposure. A practical response is to map the supply chain against MoCRA's documentation requirements before any external inquiry begins. Companies that already audit suppliers annually, retain current safety dossiers, and document adverse event reviews will absorb the directive with minimal disruption. The cost of remediation typically runs lower than the cost of an enforcement action.

The plain takeaway: documentation discipline becomes the cheapest insurance available.

The forward view

The directive functions as a warning shot, not a rule change. Cosmetics companies that treat MoCRA compliance as a one-time filing exercise rather than an operating discipline will find the new posture uncomfortable. Watch for the full Holland & Knight analysis, any DOJ implementation memo, and the first enforcement action brought under the directive. Those three signals will determine whether the new posture produces cases or merely guidance.

The plain takeaway: the next signal to watch is whether the directive produces cases or merely guidance.

Marcus Bennett covers regulatory developments affecting the cosmetics and personal care industry.